Michael J Gigliotti1, Shaakir Hasan1, Yun Liang1, Douglas Chen2, Russell Fuhrer1, Rodney E Wegner1. 1. Allegheny Health Network Cancer Institute, Division of Radiation Oncology, 320 East North Ave, Pittsburgh, PA 15212, USA. 2. Allegheny Health Network, Division of Otolaryngology, 320 East North Ave, Pittsburgh, PA 15212, USA.
Abstract
OBJECTIVE: Patients with paragangliomas were treated with LINAC-SRS/SRT in this retrospective review to evaluate tumor control, clinical control, and toxicity. METHODS: 16 patients (median age = 65) with paragangliomas were treated with LINAC-SRS/SRT. Patients were treated to a median dose of 25 Gy in 5 Fx and were evaluated for long-term tumor control, symptom control, and toxicity. Median follow-up was 44 months. RESULTS: 16 paragangliomas with a median PTV of 11.7 cc were treated as above. All but 2 lesions were controlled at last follow-up, with a 5-year control rate of 88%. Eighty-one percent of patients reported improved or resolved symptoms after treatment. Toxicities included grade 2 vertigo in 1 patient and grade 3 headache from hydrocephalus requiring ventriculoperitoneal shunt. DISCUSSION: Linear accelerator based SRS/SRT appears to be an effective treatment option for paragangliomas. Recurrences in this cohort occurred 4-5 years after treatment, highlighting the importance of long term follow up.
OBJECTIVE: Patients with paragangliomas were treated with LINAC-SRS/SRT in this retrospective review to evaluate tumor control, clinical control, and toxicity. METHODS: 16 patients (median age = 65) with paragangliomas were treated with LINAC-SRS/SRT. Patients were treated to a median dose of 25 Gy in 5 Fx and were evaluated for long-term tumor control, symptom control, and toxicity. Median follow-up was 44 months. RESULTS: 16 paragangliomas with a median PTV of 11.7 cc were treated as above. All but 2 lesions were controlled at last follow-up, with a 5-year control rate of 88%. Eighty-one percent of patients reported improved or resolved symptoms after treatment. Toxicities included grade 2 vertigo in 1 patient and grade 3 headache from hydrocephalus requiring ventriculoperitoneal shunt. DISCUSSION: Linear accelerator based SRS/SRT appears to be an effective treatment option for paragangliomas. Recurrences in this cohort occurred 4-5 years after treatment, highlighting the importance of long term follow up.
Entities:
Keywords:
glomous jugulare tumor; linear accelerator-based fractionated sterotactic radiotherapy (SRT); paraganglioma; single fraction (Fx) sterotactic radiosurgery (SRS)
Authors: R Liscák; V Vladyka; B Wowra; A Kemeny; D Forster; J A Burzaco; R Martinez; S Eustacchio; G Pendl; J Regis; W Pellet Journal: Acta Neurochir (Wien) Date: 1999 Impact factor: 2.216
Authors: Philip Gilbo; Christopher G Morris; Robert J Amdur; John W Werning; Peter T Dziegielewski; Jessica Kirwan; William M Mendenhall Journal: Cancer Date: 2014-07-24 Impact factor: 6.860
Authors: Tyler W Winford; Leighanne H Dorton; James D Browne; Michael D Chan; Stephen B Tatter; Eric R Oliver Journal: Otol Neurotol Date: 2017-04 Impact factor: 2.311
Authors: Stephen G Chun; Lucien A Nedzi; Kevin S Choe; Ramzi E Abdulrahman; Susie A Chen; John S Yordy; Robert D Timmerman; Joe W Kutz; Brandon Isaacson Journal: Stereotact Funct Neurosurg Date: 2014-05-07 Impact factor: 1.875
Authors: Martin Henzel; Klaus Hamm; Markus W Gross; Gunnar Surber; Gabriele Kleinert; Thomas Failing; Helmut Sitter; Gerd Strassmann; Rita Engenhart-Cabillic Journal: Strahlenther Onkol Date: 2007-10 Impact factor: 3.621
Authors: Mohammad Maarouf; Jürgen Voges; Peter Landwehr; Rainer Bramer; Harald Treuer; Martin Kocher; Rolf-Peter Müller; Volker Sturm Journal: Cancer Date: 2003-02-15 Impact factor: 6.860
Authors: R Garcia-Carbonero; F Matute Teresa; E Mercader-Cidoncha; M Mitjavila-Casanovas; M Robledo; I Tena; C Alvarez-Escola; M Arístegui; M R Bella-Cueto; C Ferrer-Albiach; F A Hanzu Journal: Clin Transl Oncol Date: 2021-05-06 Impact factor: 3.405